Universidad Austral de Chile
🇨🇱Chile
Clinical Trials
5
Active:0
Completed:1
Trial Phases
3 Phases
Phase 1:1
Phase 3:2
Phase 4:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 3
2 (50.0%)Phase 1
1 (25.0%)Phase 4
1 (25.0%)Effectiveness of 3D Bone Matrix in Cranioplasty
Phase 3
- Conditions
- CranioplastyCraniotomyCraniocerebral InjuriesCraniotomy ClippingCraniotomy SurgeryCraniocerebral Trauma
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Universidad Austral de Chile
- Target Recruit Count
- 8
- Registration Number
- NCT06792864
- Locations
- 🇨🇱
Hospital Base de Valdivia, Valdivia, Chile
Effectiveness of 3D-printed Patient-specific Resorbable Scaffolds for Maxillary Bone Regeneration
Phase 3
- Conditions
- Bone LossJaw, EdentulousEdentulous MouthJaw FracturesBone Loss, Age Related
- First Posted Date
- 2025-01-14
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Universidad Austral de Chile
- Target Recruit Count
- 10
- Registration Number
- NCT06773923
- Locations
- 🇨🇱
Valdivia, Valdivia, Chile
Meloxicam Versus Ibuprofen for Pain Control After Third Molar Exodontia in Adult Patients
- First Posted Date
- 2024-11-25
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Universidad Austral de Chile
- Target Recruit Count
- 68
- Registration Number
- NCT06704113
Efficacy of an Intradialysis Combined Training Program on Disability Level and Physical Performance.
- Conditions
- Chronic Renal Failure
- First Posted Date
- 2016-08-30
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- Universidad Austral de Chile
- Registration Number
- NCT02883309
Efficacy Study of Andrographis Paniculata Purified Standardized Extract (ApE) in Patients With Multiple Sclerosis (MS)
Phase 1
Completed
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: 2 - ExcipientsDrug: 1 - Andrographis paniculata p/st extract
- First Posted Date
- 2014-11-02
- Last Posted Date
- 2016-06-23
- Lead Sponsor
- Universidad Austral de Chile
- Target Recruit Count
- 30
- Registration Number
- NCT02280876
- Locations
- 🇨🇱
Hospital Regional, Valdivia, Los Ríos, Chile
News
First Nanobody Treatment Shows Promise Against Deadly Nipah and Hendra Viruses
University of Queensland researchers have identified DS90, the first nanobody capable of neutralizing both Nipah and Hendra viruses, for which no approved vaccines or cures currently exist.